Baird lowered the firm’s price target on Danaher (DHR) to $277 from $278 and keeps an Outperform rating on the shares. The firm noted they reported 3Q results ahead of expectations, driven by Biotechnology and Cepheid respiratory upside. Baird said they remain constructive on the medium-term outlook/portfolio, though initial 2025 guidance assumptions and the pace of broader end-market improvements remain outstanding questions.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $275 from $285 at Barclays
- Danaher price target raised to $255 from $250 at Goldman Sachs
- Morning Movers: 3M gains and GE Aerospace falls following third quarter results
- Danaher backs FY24 revenue view down low-single digits
- Danaher reports Q3 adjusted EPS $1.71, consensus $1.57